Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 14/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 10/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE2A | O00408 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | PDE5A | O76074 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Papaverine SCHEMBL29387160 | 1.00 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL34702 | 1.00 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL9551009 | 1.00 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL28169527 | 0.99 | PDE10A (0.97) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29696479 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL8691148 | 0.99 | PDE10A (0.97) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL677440 | 0.99 | PDE10A (0.97) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL29356374 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL9614479 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 | |
| Papaverine SCHEMBL5500363 | 0.99 | PDE10A (1.00) | PDE10APDE3APDE3BSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119144726-A | Method for improving tumor detection sensitivity through gene methylation signal pre-amplification | 昆明市延安医院(昆明市干部疗养院) | 2024-12-17 | — | — | CN | claimed |
| CN-116859404-A | Moon laser ranging system | 中国科学院云南天文台 | 2023-10-10 | — | — | CN | claimed |
| CN-115135669-B | Modified Fc region | 硕腾服务有限责任公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2026098549-A1 | METHOD EXECUTED BY USER EQUIPMENT, AND USER EQUIPMENT | 夏普株式会社 | 2026-05-15 | — | — | WO | disclosed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260116997-A1 | METHODS AND COMPOSITIONS FOR TREATING MMP-9 MEDIATED DISORDERS | ASHIBIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260110013-A1 | PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN | AMGEN INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-3719122-B1 | SIALYLATED GLYCOPROTEINS | MOMENTA PHARMACEUTICALS INC (US) | 2026-04-01 | — | — | EP | disclosed |
| EP-4709760-A2 | HIGH CONCENTRATION FORMULATIONS FOR MONOCLONAL ANTIBODIES | Icahn School of Medicine at Mount Sinai (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4707306-A2 | ANTIBODIES TO PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) AND USES THEREOF | Sanofi (FR) | 2026-03-11 | — | — | EP | disclosed |
| EP-4704703-A1 | METHODS AND SYSTEMS FOR TRANSLATION OF NEURAL ACTIVITY INTO EMBODIED DIGITAL-AVATAR ANIMATION | The Regents of University of California (US) | 2026-03-11 | — | — | EP | disclosed |
| CN-114206316-A | Excipients for biotherapeutics | 慕尼黑路德维希-马克西米利安斯大学 | 2022-03-18 | — | — | CN | disclosed |
| US-20220079502-A1 | DEVICES AND METHODS FOR REMOTE THERAPY AND PATIENT MONITORING | AVENUE VENTURE OPPORTUNITIES FUND II, L.P. | 2022-03-17 | — | — | US | disclosed |
| CN-114181312-A | Galactose engineered immunoglobulin 1 antibodies | 豪夫迈·罗氏有限公司 | 2022-03-15 | — | — | CN | disclosed |
| US-20220076080-A1 | System and a Method for Assessment of Robustness and Fairness of Artificial Intelligence (AI) Based Models | B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-03-10 | — | — | US | disclosed |
| US-20220056109-A1 | GLYCOPROTEINS WITH ANTI-INFLAMMATORY PROPERTIES | MOMENTA PHARMACEUTICALS, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11244698-B2 | Systems and methods for identifying human emotions and/or mental health states based on analyses of audio inputs and/or behavioral data collected from computing devices | COGITO CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| WO-2022023528-A1 | CYTOSOLIC DELIVERY | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2022-02-03 | — | — | WO | disclosed |
| US-11236159-B2 | Methods of treating FGF21-associated disorders | NOVARTIS AG (CH) | 2022-02-01 | — | — | US | disclosed |
| WO-2022016260-A1 | METHODS AND SYSTEMS FOR DIGITAL IMAGE-REFERENCED INDIRECT TARGET AIMING | KWESST, INC. (CA) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116997-A1 | METHODS AND COMPOSITIONS FOR TREATING MMP-9 MEDIATED DISORDERS | MMP9, MMP11, MMP10 | PDE10A 1976/4885PDE3A 1819/4885PDE3B 2082/4885 |
| US-20260110013-A1 | PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN | FUCA2, FUCA1, GOLIM4 | PDE10A 4795/4885PDE3A 4875/4885PDE3B 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.